Current and Emerging Trends in Chronic Myeloid Leukemia

Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Jorge E. Cortes, MD, discusses the future of ponatinib in the treatment of patients with chronic myeloid leukemia.

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Kendra Sweet, MD, discusses efforts made to mitigate toxicities associated with ponatinib in patients with chronic myeloid leukemia.

Gabriela Hobbs, MD, shares advice on how to choose the appropriate second-line treatment option for patients with chronic lymphocytic leukemia who are resistant to TKIs.

Jorge E. Cortes, MD, shares advice for navigating among first- and second-generation TKIs in the frontline treatment of patients with chronic myeloid leukemia.

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.